Proportion of participants who required further glaucoma surgery, including laser · people with cataracts and open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication
Cataract surgery with Hydrus microstent may leads to lower proportion of participants who required further glaucoma surgery,… compared with cataract surgery alone (low certainty).
1 finding from 1 review
Glaucoma progression at 12 months, measured by additional visual field defects · people with cataracts and open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in health‐related quality of life · people with cataracts and open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraoperative and postoperative complications · people with cataracts and open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Proportion of participants who were medication‐free (not using eye drops) short‐term · people with open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication
Hydrus microstent may leads to higher proportion of participants who were medication‐free (not using eye… compared with iStent trabecular micro‐bypass stent (low certainty).
1 finding from 1 review
Mean change in unmedicated IOP (after washout) measured using Goldmann applanation tonometry short‐term · people with open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Tezepelumab (1 RCT; 56 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in tezepelumab (1 RCT; 56 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Lebrikizumab (1 RCT; 156 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes lebrikizumab (1 RCT; 156 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
PF‐04965842 (1 RCT; 211 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes PF‐04965842 (1 RCT; 211 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Tralokinumab (1 RCT; 153 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes tralokinumab (1 RCT; 153 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Apremilast (1 RCT; 121 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in apremilast (1 RCT; 121 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Baricitinib (1 RCT; 75 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes baricitinib (1 RCT; 75 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 6 RCTsTotal participants: 1720 · patients with moderate to severe eczema
1 finding from 1 review
Intervention not reported
Dupilumab (3 RCTs; 1082 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in dupilumab (3 RCTs; 1082 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Methotrexate (1 RCT; 50 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes methotrexate (1 RCT; 50 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Fezakinumab (1 RCT; 40 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes fezakinumab (1 RCT; 40 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
QGE031 (1 RCT; 10 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes QGE031 (1 RCT; 10 participants) (very low certainty).
1 finding from 1 review